Torrent Pharmaceuticals Ltd (TORNTPHARM) Q4FY25 Concall Summary - Mar-2025 Qtr
Performance Overview
- Torrent Pharmaceuticals demonstrated strong performance in its branded markets, contributing 73% of total revenue in Q4 FY25.
- India business achieved a 12% growth in Q4.
- US generics business grew by 15%, while Germany saw a 2% growth.
- Brazil experienced 5% constant currency growth, impacted by an 11% Brazilian Real depreciation.
- The company anticipates high single-digit growth in Germany in future quarters due to increased tender wins.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.